AMOEBA (EPA:AMEBA) - Half-year review of the liquidity contract

Transparency directive : regulatory news

04/07/2017 17:45

PRESS RELEASE

Lyon (France), 4th July 2017

Half-year review of the liquidity contract

Pursuant to the liquidity contract established by AMOEBA with PORTZAMPARC
Trading Company, as of 30th June 2017, the liquidity account held the following
assets:

* 10 369 AMOEBA shares
* EUR 54,976.33

It is recalled that at the time of implementation, the following amount was
held in the liquidity account:

* EUR 200,000.00

About AMOEBA:
AMOEBA group's objective is to become the global leader in eliminating
waterborne bacterial risk in water treatment and wound care applications. Our
solutions represent alternatives to chemical products widely used in the
cooling water treatment and the wound care market. In a global market for
chemical biocides estimated to be worth EUR 21 bn(1) AMOEBA is focusing on the
industrial cooling tower application estimated at EUR 1.7 bn(2). Similarly, in
a global wound care market estimated at EUR 15.2bn(3), AMOEBA is targeting the
chronic wound care market in the USA, estimated to be worth EUR 751 million(4).
The use of Willaertia magna C2c Maky in health care products will be subject to
FDA (Food and Drug Administration) clearance in the USA. AMOEBA's biological
biocide for water treatment, BIOMEBA, has not yet been granted marketing
authorization in the USA, Europe and Canada. AMOEBA is taking the required
regulatory steps to be granted marketing authorization in those regions for the
use of BIOMEBA in cooling water systems. Based in Chassieu (Lyon, France),
AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and
joined the CAC(r) Small index on 21st September 2015. More information on
www.amoeba-biocide.com.

Contacts:

Amoéba
Nathalie COMBROUSSE
Marketing Communication Manager
Tel. : +33 (0)4 81 09 18 15
nathalie.combrousse@amoeba-biocide.com

Actifin
Ghislaine GASPARETTO
Financial Communication
Tel. : +33 (0)1 56 88 11 11
ggasparetto@actifin.fr

(1) : Sources combinées par Amoéba venant des traiteurs d'eau, de Freedonia,
d'Eurostat et MarketsandMarkets
(2) : Données Amoéba combinées à partir des sources : DRIRE 2013, Eurostat,
ARHIA 2013
(3) : marketsandmarkets.com, "Wound Care Market by Product, Wound Type, End
User - Global Forecast to 2021," 2016.
(4) : BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017.

source : webdisclosure.com

AMOEBA's latest news

07/10/2024 17:45

AMOEBA (EPA:AMEBA) - Half-year review of the liquidity contract

Transparency directive : regulatory news

AMOEBA's latest news

Other stories